Gliomatosis cerebri
As gliomatosis cerebri is a primary brain tumor called, in which the diffuse infiltration of the brain tissue, which also features other gliomas, as far as is in the foreground that solid fractions not occur. The disease is generally very rare, however, to assume that misdiagnosis due to the relatively little known are frequent. Some forms of encephalitis may represent clinically similar.
Epidemiology
Only about 200 cases have been reported worldwide. In general, adults are concerned, individual cases were also observed in children.
Meanwhile, cases have been reported in dogs.
Histology
The tissue of origin is glial, with the distinction of astrocytic or oligodendrozytärer cell line can not necessarily be taken. Typical is the infestation of both cerebral hemispheres, and the brainstem, cerebellum, and spinal cord can be affected. The exact pathogenic mechanisms are unclear, it is believed a progressive de-differentiation. The individual cells are intrinsically less malignant, because of the particular growth pattern must be the gliomatosis cerebri but to malignant brain tumors include. According to the WHO classification of tumors of the central nervous system, it is considered one of the grade III tumors.
Symptoms
As with other brain tumors, the localization of the discomfort is significant, often include headaches, seizures, and mental changes.
Diagnosis
Diagnosis is made by imaging ( CT, MRI) and / or biopsy.
Therapy
One surgical therapy is the gliomatosis cerebri inaccessible. Irradiation is possible, which then often the entire brain and spinal cord must be irradiated because of the long and difficult circumscribed extent of the tumor. For standard chemotherapy regimens (eg PCV) temporary remissions have been described, temozolomide seems especially in slowly progressive Gliomatosen to have a beneficial effect. A definitive cure is not possible. The median survival time is specified, at 14.5 months.
Swell
- K. Poeck, W. Hacke: Neurology. ( 10th edition ), Springer, Berlin, 1998. ISBN 3-540-63028-7.